This inventor holds 12 USPTO granted patents and 13 published patent applications, plus 2 CIPO patents and 12 EPO patents. Top assignees: Affiris Ag, Ac Immune Sa, Advantage Therapeutics, Inc.. Active years: 2013-2026.
Company Filing History:
10 out of 25 
1 out of 68 
1 out of 3 Years Active: 2013-2026
Title: The Innovative Mind of Markus Mandler: Advancements in Synucleinopathy Treatments
Introduction
Markus Mandler, a distinguished inventor based in Vienna, Austria, has made significant contributions to the field of biotechnology. With a remarkable portfolio of 11 patents, Mandler is focused on developing innovative treatments that target complex neurological conditions, particularly synucleinopathies such as Alzheimer's Disease. His innovative spirit and dedication to research and development make him a prominent figure in the medical field.
Latest Patents
Mandler's most recent patents demonstrate his cutting-edge work in the treatment of synucleinopathies. His latest innovations include a suite of mimotopes of alpha-synuclein and vaccines aimed at treating these debilitating diseases. The patented peptide sequences, such as (C)DQPVLPD (SEQ ID NO: 59) and (C)HDRPVTPD (SEQ ID NO: 70), show promising potential in therapeutic applications. Additionally, his method for treating Alzheimer's Disease involves the use of an immune-stimulating pharmaceutical composition comprising an aluminum salt, which may offer new hope for patients at risk of developing this condition.
Career Highlights
Throughout his career, Markus Mandler has contributed to various esteemed organizations, notably working with Affiris AG and Advantage Therapeutics, Inc. His roles in these companies have allowed him to spearhead innovative research efforts and collaborate with leading experts in the medical and pharmaceutical sectors.
Collaborations
Mandler's collaborative approach has been vital in his research pursuits. He has worked alongside notable colleagues such as Frank Mattner and Harald Weninger. Together, they have leveraged their expertise to advance the understanding and treatment of neurodegenerative diseases, ultimately aiming to improve patient outcomes through their collective innovations.
Conclusion
In summary, Markus Mandler stands out as a pioneering inventor in the realm of biotechnology. His ongoing research and development of treatments for synucleinopathies not only highlight his inventive capabilities but also underscore the importance of collaboration in tackling complex health challenges. With a solid foundation of patents to his name, Mandler's contributions hold the promise of transformative impacts in the field of medicine.